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Abstract  22 
Background  23 
The effects on ventricular repolarisation – recorded on the ECG as lengthening of the QT interval – of 24 
acute tuberculosis and those of standard and alternative anti-tuberculosis regimens are under-25 
documented. A correction factor (QTc) is introduced to make the QT independent of the heart rate, 26 
translating into the slope of the regression line between QT and heart rate being close to zero. 27 
Methods 28 
ECGs were performed pre- and  1-5 hours post-dosing (month 1, 2, end of treatment) around drugs’ 29 
peak concentration time in tuberculosis patients treated with either the standard 6-month treatment 30 
(rifampicin and  isoniazid for 6 months, pyrazinamide and ethambutol for 2 months; “control”) or a test 31 
regimen with gatifloxacin, rifampicin and isoniazid given for 4 months (pyrazinamide for the first 2 32 
months) as part of the OFLOTUB study, a randomized controlled trial conducted in five African countries. 33 
Drug levels were measured at steady-state (month 1) in a subset of patients. We compared treatment 34 
effects on the QTc and modelled the effect of individual drugs’ Cmax on the Fredericia-corrected QT 35 
interval.  36 
Results 37 
1686 patients were eligible for the correction-factor analysis of QT at baseline (mean age 30.7 years, 38 
27% female). Median heart rate decreased from 96/min at baseline to 71/min at end of treatment, and 39 
body temperature from 37.2 to 36.5 C. Pre-treatment, the non-linear model estimated the best 40 
correction factor at 0.4081 in-between Bazett’s (0.5) and Fridericia’s (0.33) corrections. On treatment, 41 
Fridericia (QTcF) was the best correction factor.  42 
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1602 patients contributed to the analysis of QTcF by treatment arm. The peak QTcF value during follow-43 
up was >480ms for 21 patients (7 and 14 in the test and control arm) and >500ms for 9 (5 and 4, 44 
respectively), corresponding to a risk difference of  -0.9% (95% CI: -2.0% to 2.3%, p=0.12) and  0.1% (95% 45 
CI: -0.6% to 0.9%, p=0.75), respectively between the test and control arms. 106 (6.6%) patients had a 46 
peak measurement change from baseline >60ms (adjusted between-arm difference 0.8%, 95% CI -1.4% 47 
to 3.1%, p=0.47).  No evidence was found of an association between  Cmax of the anti-tuberculosis drugs 48 
1 month into treatment and the length QTcF.  49 
Conclusions 50 
Neither a standard 6-month nor a 4-month gatifloxacin-based regimen appear to carry a sizeable risk of 51 
QT prolongation in patients with newly-diagnosed pulmonary tuberculosis.  This is to-date the largest 52 
dataset studying the effects of anti-tuberculosis regimens on the QT, both for the standard regimen and 53 
for a fluoroquinolone-containing regimen. 54 
  55 
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Introduction  56 
The time for ventricular depolarisation and repolarisation is measured on the surface electrocardiogram 57 
(ECG) as the time from the start of the Q wave to the end of the T wave. Prolonged repolarisation is 58 
recorded on ECG as lengthening of the QT interval (1). This condition is considered to increase the risk 59 
for ventricular arrhythmias and the potentially fatal ‘Torsade de Pointe’ (TdP). Ventricular repolarisation 60 
is mediated mostly by the outflow of potassium (K+) from the myocytes. Attenuation of the voltage-61 
dependent K+ channels’ ability to repolarize can prolong the QT interval and create the conditions for 62 
TdP.  63 
There is very little knowledge about how acute tuberculosis affects the QT interval, or about the 64 
potential for anti-tuberculosis treatments to affect ventricular repolarisation. With prospects of having 65 
them added to the anti-tuberculosis armoury of drugs, drugs belonging to the fluoroquinolone (FQ) 66 
family have attracted attention, as they can variably affect ventricular repolarisation(2). These drugs 67 
have different affinities for binding to the rapid component of the delayed-rectifier current IKr, which is 68 
expressed by the human ether-a-go-go-related gene hERG(3). In particular, it has been suggested that 69 
compounds such as gatifloxacin and moxifloxacin, both considered in anti-tuberculosis regimens, which 70 
have a methoxy substitution at position C8, might inhibit hERG at therapeutically-achievable 71 
concentrations(4). 72 
Establishing the risk for QT prolongation associated with the use of a drug is not straightforward. 73 
The length of the QT interval varies during the day and from day to day and with gender and age, and is 74 
influenced by potassium levels, body temperature, heart rate (HR), and factors such as disease and 75 
drugs. It is customary to introduce a correction factor to account for the effect of the heart rate (heart 76 
rate-corrected QT, or QTc). The correction factor is introduced to make the QT independent of the heart 77 
rate, hence the need for the slope of the regression line to be as close to zero when the QT is plotted 78 
against the heart rate. The QTc is calculated by dividing the QT by RR (calculated as 60 / heart rate). The 79 
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International Conference for Harmonisation (ICH) recommends analysing the QT using the Bazett and 80 
the Fridericia corrections (QTcB and QTcF), which use fixed exponents of 0.5 and 0.33, respectively, for 81 
the RR, and exploring other corrections whenever appropriate. The Bazett correction QTcB (QT/RR0.5) is 82 
considered most suited for HR  60 – 100 bpm (it under-corrects if HR < 60 and over-corrects if HR > 100 83 
bpm); the Fridericia formula QTcF (QT/RR0.33) is generally regarded as more appropriate outside this 84 
range. Various other corrections exist.  Population-based corrections are also recommended for specific 85 
conditions (5, 6). There is no information on the appropriateness of these corrections in patients with 86 
pulmonary tuberculosis (PTB) – i.e. how good they are in making the QT interval independent of the 87 
heart rate. 88 
 We analysed the QT of patients with PTB enrolled in a randomised trial with a non-inferiority 89 
design comparing the standard 6-month treatment to a gatifloxacin-containing 4-month regimen (the 90 
OFLOTUB trial) (7). We also evaluated the effect of exposure, expressed as Cmax of the individual drugs of 91 
both treatment arms, in the patients who participated in a pharmacokinetic sub-study (nested 92 
pharmacokinetic/pharmacodynamic (PK/PD) study).    93 
 94 
Materials and methods 95 
Study design 96 
The study was a non-inferiority randomized, open-label, controlled trial, conducted in five African 97 
countries: Benin, Guinea, Kenya, Senegal and South-Africa with a nested PK/PD study for subset of 98 
patients. Its objective was to assess the efficacy and safety of a gatifloxacin containing 4-month regimen 99 
for the treatment of drug-susceptible pulmonary tuberculosis compared to standard World Health 100 
Organisation recommended 6-month treatment (8). The protocol was approved by relevant ethics 101 
committee and regulatory authorities of all partner’s institutions. This study was registered at Clinical-102 
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Trials.gov under registration number NCT00216385. More details on study design have been published 103 
elsewhere (7). 104 
Subjects  105 
Male and female patients, aged 18 to 65 years, newly diagnosed with microscopically-proven pulmonary 106 
tuberculosis and providing informed consent for inclusion in the trial were considered for enrolment. 107 
Patients with congenital QTc interval prolongation >480 ms, clinically significant bradycardia (40 108 
beats/minute), hypokalaemia grade 1 and above (i.e. < 3.0 mEq/l), and patients using drugs known to 109 
prolong QT interval, were excluded at enrolment.  110 
Treatment arms 111 
Patients were randomised, stratified by country, to one of two treatment arms. The control treatment 112 
regimen included isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E) given daily for 2 113 
months followed for 4 months with isoniazid and rifampicin (i.e. 2RHEZ/4RH). In the intervention arm 114 
(referred to as test), gatifloxacin (G) was substituted for ethambutol in the 2-month intensive phase and 115 
was maintained for the 2-month continuation phase (i.e. 2RHGZ/2GRH). Gatifloxacin was given at a dose 116 
of 400 mg per day, irrespective of body weight. The doses of HRZE followed World Health Organization 117 
(WHO) recommendations (8) and were provided as fixed dose combination tablets.  118 
Measurements 119 
Along with clinical and laboratory evaluations, twelve-lead electrocardiograms (ECGs) were performed 120 
at baseline (pre-treatment), at months 1 and 2 of TB treatment and at the end of the treatment. ECGs 121 
were obtained with a Shiller CP300 machine which was configured to report automatically QT intervals 122 
automatically and to calculate the corrected QT interval (QTc) by Bazett’s formula. Exact heart rate at 123 
the time of ECG measurement was also automatically measured and recorded. This allowed us to 124 
calculate a posteriori QTc interval using other formulas such as Fredericia’s. The following information 125 
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was also recorded for each patient: gender, age, medical history, vital signs (including body 126 
temperature), clinical examination and concomitant medication.  127 
Plasma samples were taken for drug concentration measurements at baseline and month 1 as part of a 128 
population PK study. Patients were randomised to one of three sampling schedules (A, B and C), each 129 
with three sampling times: (A) Sample 1: within the hour before the treatment dose (-1 to 0 hours),  130 
Sample 2: between 1 and 2 hours after the treatment dose, Sample 3: between 2.5 and 3.5 hours after 131 
the treatment dose; (B) Sample 1: between 1 and 2 hours after the treatment dose, Sample 2: between 132 
2.5 and 3.5 hours after the treatment dose, Sample 3: between 4 and 6 hours after the treatment dose; ( 133 
C) Sample 1: between 1 and 2 hours after the treatment dose, Sample 2: between 2.5 and 3.5 hours 134 
after the treatment dose, Sample 3: between 8 and 10 hours after the treatment dose. 135 
Population pharmacokinetic models were used to generate individual estimates of peak drug 136 
concentration (Cmax) and time to Cmax (Tmax) at steady state. (9,10) 137 
Drug safety was closely monitored during the course of the study in compliance with ICH/GCP 138 
guidelines. 139 
Statistical methods 140 
Review of the correction factor 141 
The QT measurement at enrolment, combined across treatment arm, was used to assess the correction 142 
factor in this sample of TB patients. We calculated the linear regression coefficients of gradient and 143 
intercept for the Bazett corrected (correction factor RR0.5) and Fridericia-corrected (correction factor 144 
RR0.33) QT against 1-RR. These analyses were repeated for each measurement post randomisation: 145 
month 1 , month 2 and at the end of treatment (either month 4 or 6 for the test and control arms, 146 
respectively) combined across treatment arm for the purpose of assessing the adequacy and robustness 147 
of the correction factors. 148 
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In addition, a non-linear model was fitted to the uncorrected QT at baseline to estimate the population-149 
specific correction factor for the pre-treatment patients with active pulmonary tuberculosis. 150 
Definition of outcomes 151 
According to ICH guidelines (6), QTc data are presented as both continuous and binary variables using 152 
the Fridericia correction (QTcF). Continuous measurements were summarised using the arithmetic 153 
mean, standard deviation (sd). Peak QTc was defined as the maximum QTc interval from up to a possible 154 
3 follow-up recordings (week 4, 8 or end of treatment).  155 
Between-treatment arm comparisons 156 
Peak QTcF during follow-up and change of this measurement from baseline were compared between 157 
treatment arms using linear regression, adjusting for country where possible.   Peak values were also 158 
classed as binary variables using cutpoints at >450ms >480ms, and >500ms, and change from baseline as 159 
>60ms; between-treatment comparisons were expressed as risk difference, adjusted for country. 160 
Patients with a baseline measurement and at least one follow-up measurement contribute to these 161 
analyses. 162 
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PKPD analysis 163 
In the subset of patients who have drug concentrations measurements, the effect of Cmax, for each drug 164 
separately, on QTcF at month 1 was assessed using linear regression, adjusting for country, sex, age and 165 
QTcF at enrolment, and study arm (only adjusting for study arm for the effect of Cmax for isoniazid, 166 
rifampicin and pyrazinamide). 167 
  168 
Results 169 
Patients’ characteristics 170 
Of the 1692 patients in the ITT population, 1686 (99.6%) were eligible for the correction-factor analysis 171 
of QT at baseline (see flow diagram Figure 1).  Mean age was 30.7 years, 27% were female, 18% HIV-172 
positive, 51% had cavitation and 25% had a temperature >37.7o C (Table 1).  173 
Heart rate and Temperature  174 
Median heart rate decreased progressively from 96/min at baseline throughout treatment to reach 71 at 175 
end of treatment. Median baseline body temperature was 37.2 and decreased to approximately 36.5 on 176 
treatment. The percentage of participants with temperature >37.7o C fell over follow-up to 2.7% 177 
(43/1582) and 2.4 % (37/1539) at months 1 and 2 after the start of TB treatment, respectively, and to 178 
0.7% (10/1445) at the end of treatment. (Table 2) 179 
Correction factors  180 
In these patients with active PTB about to initiate treatment, the uncorrected QT increased with the 181 
heart rate overall (coefficient -202.7 95% confidence interval [CI] -209.6 to -195.9, adjusted R2 = 0.67) 182 
(Table 3).  183 
At baseline, neither the Bazett and Fridericia corrections were optimal; QTcB tended to under-184 
correct (gradient 51.8, 95% CI 43.5, 60.1) and QTcF over-correct (gradient -46.3, 95% CI -54.1, -38.5) the 185 
QT (Fig 2, Table 3). The non-linear model estimated the correction factor to be 0.4081 (95% CI 0.3949, 186 
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0.4213) (QTcTB), in between the Bazett and Fridericia correction factors. This correction factor was 187 
independent of the country, sex and presence or absence of cavitation (Fig 3) 188 
Applying the Bazett, Fridericia and the new correction factor to QT data measured 1 and 2 189 
months after the start of TB treatment and at the end of treatment (month 4 in the test arm and month 190 
6 in the control arm) showed the QTcF to be a better correction, with the gradient coefficient close to 191 
zero (Table 3).  192 
Between-treatment comparison 193 
The QTcF was therefore applied for between-treatment comparisons. A total of 1602 patients 194 
contribute to these analyses (Fig 1). Baseline characteristics were similar between the two treatment 195 
arms (Table 1).  196 
The peak QTcF value during follow-up was >480ms in 21 patients overall: 0.9% (7/804) and 1.8% 197 
(14/798) in the test and control arms, respectively (Table 3). There were nine occasions of QTcF >500ms 198 
(see Table 3 and Table 4). Five occurred in the test arm (0.6%) at month 1 (506 and 514ms), month 2 199 
(518ms) and month 4 (502 and 511ms), and four in the standard treatment arm (0.5%) at month 2 (510 200 
and 517ms) and month 6 (507 and 569ms).  The risk difference for QTcF >480ms and >500 were -0.9% 201 
(95% CI: -2.0% to 2.3%, p=0.12) and 0.1% (95% CI: -0.6% to 0.9%, p=0.75), respectively, between the test 202 
and control arms. Overall 107 (6.7%) patients had a peak measurement change from baseline >60ms, 203 
with no difference between the two treatment arms (adjusted difference 0.7%, 95% CI -1.5% to 3.0%, 204 
p=0.53).  205 
The overall mean peak QTc value was moderately higher in the test versus control arm; adjusted 206 
mean difference 2.6ms (95%CI 0.2, 4.9)ms, p=0.030). The mean and 95%CI QTcF values at baseline, 207 
month 1, month 2 and end of treatment were: 384.7ms (383.2-386.1), 394.2ms (392.6-395.7), 395.7ms 208 
(394.1-397.3), and 395.9ms (394.2-397.5) for the test arm; and 385.1ms (383.6-386.6), 391.6ms (390.1-209 
393.2), 391.7ms (390.1-393.3), and 394.9ms (393.1-396.7) for the control arm, respectively. (Fig 4) 210 
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 211 
Drug levels 212 
Pharmacokinetic measures were available for 291 patients at month 1 (144 and 147 respectively in the 213 
test and control arms). The Cmax, Tmax and AUC achieved by the individual drugs in the two treatment 214 
arms are summarised in Table 5. There was no evidence that Cmax of any of the drugs individually were 215 
associated with QTc-F at month 1 (see Table 5). 216 
 217 
Discussion 218 
This study shows that the risk of QT prolongation with either a 4-month regimen including gatifloxacin or 219 
a standard 6-month treatment is low: only  five (0.6%) and four (0.5%) subjects respectively had a value 220 
>500 ms, and 7% and 6.3% had a prolongation relative to their baseline value of >60 ms.  221 
We also found that in this African population with active PTB, the Bazett formula QTcB 222 
(QT/RR0.5) under-corrects, and the Fridericia formula QTcF (QT/RR0.33) over-corrects QT as RR increases; 223 
the QTcTB (QT/RR0.4081) fits best this population. For instance, screening patients for values >480 ms with 224 
the QTcF would have missed 1 of the 2 cases, and the QTcB would have excluded 3 more cases. While 225 
the TB correction factor appears to befit subjects of box sexes in all the countries of this study, it will be 226 
important to verify the appropriateness of this correction on larger and more diverse TB patient 227 
populations. This may have implications for entry criteria when recruiting into a TB treatment trial, as 228 
well as measuring relative changes in the QT after treatment. As patients on treatment recover, the 229 
Fridericia formula becomes more appropriate, and QTcB and QTcTB over-estimate the prolongation 230 
(with 11, 13 and 8 cases having QTcB, and 2, 3 and 3 cases having QTcTB, >480 msec at week 4, 8 and 231 
end of treatment, respectively). The correction factor is introduced to make the QT independent of the 232 
heart rate, which translates to the regression lines displayed in Figures 2 and 3 for corrected QTc; the 233 
slope is closest to zero (a horizontal line) when using the population-specific QTcTB.  234 
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ECGs were done before starting and during anti-tuberculosis treatment. During treatment the 235 
ECGs were done 1 – 5 hours post-dosing (corresponding to the interval when drug concentrations are 236 
expected to be highest in plasma) at month 1, 2 and at the end of treatment (month 4 for the 237 
gatifloxacin-containing regimen or month 6 for standard treatment). These measurements occurred 238 
when drug concentrations were at steady-state, and patients were improving or convalescent.  239 
It is becoming increasingly clear that, while FQs are generally known to block the inward delayed 240 
rectifier current IKr through the potassium channel, QT prolongation and TdP risk cannot be considered 241 
as a class effect, as the individual FQ affinities for the hERG- IKr receptor (both in absolute terms and 242 
relative to plasma levels) vary widely.   243 
In vitro, gatifloxacin had an IC50 of 130 μM (48.8 μg/ml) for the hERG channel IKr with blocking 244 
activities for other quinolones ranging from 18 μM (sparfloxacin) as the most active to 1420 μM 245 
(ofloxacin) as the least active quinolone(4). A similar range of blocking activities for IKr has been 246 
determined in the mouse tumour cell line AT-1, with IC50 values of 0.23 μM (sparfloxacin), 26.5 μM 247 
(gatifloxacin) and 27.2 μM (grepafloxacin)(11). The influence of a series of fluoroquinolones on action 248 
potential duration (APD) was also studied in isolated Guinea pig right ventricular myocardia: while some 249 
of the drugs tested did not influence APD, gatifloxacin increased the APD by 13% at a concentration of 250 
100 μM (37.5 μg/ml); at the same concentration, sparfloxacin increased the APD by 41%, while 251 
grepafloxacin and moxifloxacin showed intermediate values of 24% and 25%, respectively(12). 252 
All the FQ tested showed  propensities for a prolongation of the QT and/or the QTc interval 253 
(Carlsson correction: QT – 0.175(RR – 300) in an in vivo anaesthetized rabbit model. The compounds 254 
were infused intravenously at a dose of 2 mg/kg/min for 30 minutes, with sparfloxacin producing the 255 
highest absolute QT prolongation (+129 ms from baseline); gatifloxacin showed a minimal prolongation 256 
of the QT interval (increase from baseline = 14 ms). Ventricular tachycardia and TdP were only elicited 257 
by sparfloxacin, and only when the infusion was extended to a duration of 60 minutes(11). A similar 258 
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model in rabbits using intravenous infusion doses of 4 mg/kg/min yielded QT and QTc interval 259 
prolongation values for gatifloxacin similar to those of sparfloxacin, with increases in interval times from 260 
about 160 ms at baseline to about 320 ms at 30 minutes after the start of the infusion(13).   261 
In order to put the non-clinical data into perspective, these concentrations that evoke cardiac 262 
effects in experimental in-vitro and in-vivo models must be compared to plasma levels achieved in 263 
patients. According to the Tequin® (gatifloxacin) label, a 400 mg intravenous bolus given to healthy 264 
volunteers leads to a Cmax of ~5.5 μg/ml, a concentration which is ~23-times lower than the IC50 for hERG 265 
inhibition and ~5-times lower than the IC50 for IKr blockade in AT-1 cells; in this phase 3 trial (oral 266 
treatment with 400 mg/d) the Cmax was 3.9 μg/ml after the first dose and 3.8 μg/ml at steady state 267 
[IC50/Cmax ratio ~34 (95%CI 21 – 54)]. Both indicate a substantially lower risk than that inferred by Kang 268 
et al(4). In addition, when applying a scaling factor of 0.324 for the dose administered to extrapolate the 269 
in vivo rabbit data to humans, the intravenous infusion of 2 mg/kg/min, resulting in only a minimal 270 
prolongation of the QT interval, will then correspond to a human equivalent bolus dose of ~20 mg/kg, or 271 
1000 mg for a 50 kg human. Similarly, the FDA data for Tequin® in mongrel dogs, where no influence on 272 
the ECG was seen at an intravenous infusion of 10 mg/kg/min, can be translated into a human 273 
equivalent bolus dose of ~162 mg/kg, or a dose of >8000 mg. All these data suggest a low risk for 274 
gatifloxacin to induce serious cardiovascular adverse events.  275 
Furthermore, there is no clear correlation between hERG- IKr receptor affinity and risk of QT 276 
prolongation or risk of TdP. The risk of TdP with FQs is in actual facts very low, and is estimated to be at 277 
~27 for 10 million prescriptions for gatifloxacin, including subjects with concomitant risk factors(14). The 278 
Uppsala Monitoring Centre database reports(15), as of 01/03/2014   a total of 13,556 cardiac adverse 279 
events with fluoroquinolones, of which 767 are QT prolongation and 451 TdP, 100 and 53 respectively 280 
with gatifloxacin, 207 and 166 with levofloxacin and 269 and 113 with moxifloxacin. Direct comparisons 281 
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are obviously not possible due to the absence of the denominator (number of people exposed to the 282 
different FQs).     283 
The main methodological limitation of this study is that there was no external review of QTc 284 
measurement, but all were measured automatically with the same machine in all study sites, and all QTc 285 
values reported in the CRF were reviewed by an external monitor; furthermore, there was only one QTc 286 
measurement done at each time point. Another potential limitation is that, assuming that Cmax is the 287 
main determinant of the risk for QT prolongation, ECGs were done during treatment when all drugs 288 
were at steady-state, but peak plasma concentrations might have been higher in the earlier phases of 289 
treatment.  290 
In summary, this study indicates that neither a standard 6-month TB treatment, nor a 4-month, 291 
six-day-a-week regimen including gatifloxacin at 400 mg/d in combination with three (rifampicin, 292 
isoniazid and pyrazinamide) other anti-tuberculosis drugs for the first two months, and two (rifampicin, 293 
isoniazid) for the following two months, appear to carry a sizeable risk of QT prolongation.  294 
These results are significant and novel for a number of reasons. To our knowledge, this is to-295 
date the largest dataset studying the QT interval during acute active tuberculosis itself, documenting  296 
the effects on the QT interval of the standard regimen as well as a fluoroquinolone-containing regimen, 297 
and investigating the relationship between drug levels and the QT. As such, they fill a knowledge gap, 298 
and are useful for future studies. It will be important to verify in other sets of patients, including those 299 
with other forms of tuberculosis, whether and how active disease affects the QT interval, and which 300 
formula is best suited to correct it so as to make it independent of the heart rate. This knowledge will 301 
improve also our understanding of treatment effects, as it will refine the classification of QT values as 302 
being normal or prolonged – both for eligibility to treatment and for assessing risks. This study also 303 
provides a reference point for other studies which will aim to evaluate the effects on ventricular 304 
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repolarisation of standard and alternative treatments on both newly-diagnosed and drug-resistant 305 
tuberculosis, as the latter in particular may include drugs with potential for QT prolongation. 306 
 307 
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Table 1: Baseline demographics and clinical variables for patients in the (i) correction factor analysis 361 
(n=1686) and (ii) the comparison of QTc by treatment arm (n=1602) 362 
 
 
Correction factor analysis (i) Between-arm comparison (ii) 
Test 
(n=845) 
Control 
(n=841) 
Test 
(n=804) 
Control 
(n=798) 
n % n % n % n % 
Country Benin  158 (18.7) 158 (18.8) 150 (18.7) 151 (18.9) 
Guinea  219 (25.9) 225 (26.7) 216 (26.9) 213 (26.7) 
Kenya  100 (11.8) 97 (11.5) 100 (12.4) 95 (11.9) 
Senegal  178 (21.1) 180 (21.4) 154 (19.1) 163 (20.4) 
South Africa 190 (22.5) 181 (21.5) 184 (22.9) 176 (22.1) 
Age, years Mean(sd)  30.81 (9.1) 30.6 (9.0) 30.8 (9.1) 30.6  (8.9) 
Sex Female  229 (27.1) 232 (27.6) 215 (26.7) 224 (28.1) 
HIV2 Positive  147 (17.5) 156 (18.8) 141 (17.6) 150  (18.9) 
Cavitation3 Yes  438 (52.0) 417 (50.0) 413 (51.5) 394 (49.8) 
Heart rate4 Mean (sd)  95.6 (17.4) 95.1 (17.8) 95.6 (17.5) 95.2 (17.5) 
Temperature5 >37.7  216 (25.6) 198 (23.6) 201 (25.0) 187 (23.5) 
BMI Mean (sd) 17.4 (4.9) 17.5 (5.0) 17.3 (4.9) 17.5 (5.0) 
1Age not known for n=1 in the test arm; 2 HIV status unknown in analysis (i) for n=11 (n=5 in the test arm, n=6 in 363 
the control arm) and in analysis (ii) for n=10 (n=5 in the test arm, n=5 in the control arm); 3 Cavitary status 364 
unknown in analysis (i)  for n=10 (n=3 in the test arm, n=7 in the control arm) and in analysis (ii)  for n=9 (n=2 in the 365 
test arm, n=7 in the control arm);  4 Heart rate unknown in analysis (ii)  for n=4 (n=2 in the test arm, n=2 in the 366 
control arm);  5 Temperature unknown in analysis (i)  for n=3 (n=1 in the test arm, n=3 in the control arm) and in 367 
analysis (ii)  n=3 (n=1 in the test arm, n=2 in the control arm) 368 
sd standard deviation; BMI body mass index  369 
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Table 2: Heart rate and Temperature during the treatment phase, restricted to samples with data 370 
available for the correction analysis 371 
  Baseline Month 1 Month 2 
End of 
treatment* 
Heart rate Median 
IQR 
n 
96 
83-106 
1686 
81 
71-95 
1562 
78 
68-90 
1512 
71 
62-81 
1402 
Temperature Median 
IQR 
n 
37.2 
36.6-37.7 
1682 
36.6 
36-37 
1582 
36.5 
36-36.9 
1512 
36.4 
36-36.9 
1445 
 >37. 7o C 
% (n/N) 
24.6% 
(414/1682) 
2.7% 
(43/1582) 
2.4% 
(37/1539) 
0.7% 
(10/1445) 
* month 4 (gatifloxacin) or month 6 (control  / IQR interquartile range 372 
 373 
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Table 3:  Linear regression coefficients (gradient and intercept) for uncorrected QT, Bazett (QTcB), Fridericia (QTcF) and new correction 
(QTcTB)  vs 1-RR at baseline (randomisation), 1 and 2 months from stat of treatment and at the end of treatment  
 
 
 
Baseline
(n=1686)  
Month 1
(n=1560) 
 Month 2(n=1512) 
End of treatment*
(n=1402) 
Uncorrected QT 
 
Gradient  (95% CI) 
Intercept (95% CI) 
R2 
-202.7 (-209.6, -195.9) 
403.8 (401.2,406.3) 
0.67 
-162.3 (-168.8, -155.8) 
396.3 (394.4, 398.3) 
0.61 
-154.5 (-161.1, -148.0) 
395.1 (393.4, 396.9) 
0.59 
-134.4 (-141.3, -126.7) 
395.1 (391.9, 395.0) 
0.48 
QTcB Gradient  (95% CI) 
Intercept (95% CI) 
R2 
51.8 (43.5,60.1) 
397.1 (394.1, 400.2) 
0.08 
80.8 (73.5, 88.1) 
394.1 (392.0, 396.3) 
0.23 
80.8 (73.6, 88.0) 
394.5 (392.5, 396.4) 
0.24 
90.0 (82.3, 97.7) 
394.7 (393.0, 396.3) 
0.27 
QTcF Gradient  (95% CI) 
Intercept (95% CI) 
R2 
-46.3 (-54.1, -38.5) 
401.0 (398.1, 403.9) 
0.075 
-9.8 (-16.8, -2.8) 
395.4 (393.3, 397.4) 
0.005 
-5.5 (-12.5, 1.4) 
394.9 (392.0, 396.7) 
0.002 
9.7 (2.2, 17.2) 
394.1 (392.5, 395.7) 
0.005 
QTcTB**  Gradient  (95% CI) 
Intercept (95% CI) 
R2 
-2.9 (-10.9, 5.1) 
399.5 (396.5, 402.4) 
0.000 
30.7 (23.6, 37.8) 
394.9 (392.8, 397.0) 
0.044 
33.3 (26.2, 40.3) 
394.7 (392.8, 396.6) 
0.053 
46.0 (38.4, 53.6) 
394.3 (392.7, 395.9) 
0.092 
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 374 
 375 
 376 
 377 
 378 
 379 
 380 
 381 
 382 
 383 
* month 4 (gatifloxacin) or month 6 (control)  ** correction factor 0.4081 (95% CI 0.3949, 0.4213) 384 
  385 
QTcB >450 5.5% (93) 7.0% (109) 6.7% (101) 6.3% (88)
>480 0.3% (5) 1.22% (19) 1.2% (18) 1.1% (16) 
>500 0.1% (2) 0.7% (11) 0.5% (8) 0.2% (3)
QTcF >450 0.24% (4) 1.7% (27) 1.3% (20) 2.2% (31)
>480 0.06% (1) 0.5% (8) 0.3% (5) 0.6% (8) 
>500 0% (0) 0.1% (2) 0.2% (3) 0.3% (4)
QTcTB** >450 0.89% (15) 2.4% (38) 2.7% (41) 3.3% (46)
>480 0.12% (2) 0.6% (10) 0.5% (8) 0.78% (11) 
>500 0.06% (1) 0.51% (8) 0.20% (3) 0.29% (4)
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Table 4: Comparison of on-treatment Fredericia correction QT values by study arm 
  Test 
(n=804) 
Control 
(n=798) 
difference  
(95% CI) 
P-value 
Peak value in follow-up Mean (sd), ms 407.2 (23.3) 404.5 (25.3) 2.6 (0.2, 4.9) 0.030
Peak value in follow-up – 
change from baseline 
Mean (sd), ms 22.9 (26.2) 19.1 (28.1) 3.8 (1.1, 6.4) 0.005 
  Risk difference (95% CI)
Peak value in follow-up >450ms1, % (n) 4.3% (35) 4.4% (35) 0.2% (-1.6%, 2.0%) 0.83
Peak value in follow-up >480ms2, % (n) 0.9% (7) 1.8% (14) -0.9% (-2.0%, 2.3%)4 0.12 
Peak value in follow-up >500ms3, % (n) 0.6% (5) 0.5% (4) 0.1% (-0.6%, 0.9%)4 0.75
Peak value in follow-up – 
change from baseline 
>60ms, % (n) 7.0% (56) 6.4% (51) 0.7% (-1.5%, 3.0%) 0.53 
1timing of peak value >450ms -  test arm n=12, 10 and 13 at month 1,2 and end of treatment, control arm n=15, 9 and 24 at month 1,2 and end of 386 
treatment; 2timing of peak value >480ms -  test arm n=3, 1 and 3 at month 1,2 and end of treatment, control arm n=5, 4 and 5 at month 1,2 and end of 387 
treatment; 3timing of peak value >500ms -  test arm n=2, 1 and 2 at month 1,2 and end of treatment, control arm n=0, 2 and 2 at month 1,2 and end of 388 
treatment;  4 not adjusted for country; CI confidence interval; sd standard deviation 389 
 390 
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 391 
Table 5: Cmax, Tmax and AUC at steady state for each drug, by study arm (n=291) 392 
Drug At steady 
state 
Test (n=144) 
Median (minimum, 
maximum) 
Control (n=147) 
Median (minimum, 
maximum) 
Estimated gradient (95% CI), 
P-value1 
Gatifloxacin Cmax  3.8 (2.5-5.8) NA -3.82 (-11.78, 4.14), 0.34 
 Tmax 1.7 (0.8-3.6) NA NA 
Ethambutol Cmax  NA 3.2 (1.5-5.5) -1.99 (-5.96, 1.98), 0.32 
 Tmax NA 2.5 (1.5-4.5) NA 
Isoniazid Cmax  3.1 (0.7-8.0) 3.1 (0.5-6.0) 0.86 (-1.11, 2.83), 0.39 
 Tmax 0.9 (0.6-3.2) 0.8 (0.3-3.6) NA
Rifampicin Cmax  6.3 (1.4-13.2) 6.9 (2.0-15.6) 0.16 (-1.08, 1.39), 0.81
 Tmax 2.2 (1.3-5.6) 1.9 (1.1-5.3) NA 
Pyrazinamide Cmax  35.9 (23.8-60.4) 35.0 (21.9-62.1) -0.28 (-0.66, 0.10), 0.15 
 Tmax 1.7 (0.9-4.5) 1.5 (0.8-5.0) NA 
1for the association of each drug Cmax individually on QTcF at month 1, adjusted for country, sex, age 393 
and QTcF at enrolment, and study arm (only for Isoniazid, Rifampicin and Pyrazinamide). CI 394 
confidence interval. 395 
  396 
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 397 
  398 
 399 
 400 
 401 
 402 
 403 
 404 
 405 
 406 
 407 
 408 
 409 
 410 
 411 
 412 
 413 
 414 
FIG 1  Study flow diagram 415 
N=1692 in the ITT analysis
N=848 in the test arm N=844 in the control arm 
In analysis of correction factor: 
(baseline data) 
N=845 in the test arm have a 
baseline measurement of QTc and 
heart rate 
In analysis of correction factor: 
(baseline data) 
N=841 in the control arm have a 
baseline measurement of QTc 
and heart rate 
In the between-arm analysis: 
N=804 in the test arm have a baseline 
measurement and at least one follow-
up measurement 
Number of follow-up measurements: 
3: n=688 (86%) 
2: n=75 (9%) 
1: n=41 (5%) 
In the between-arm analysis: 
N=798 in the control arm have a baseline 
measurement and at least one follow-up 
measurement 
Number of follow-up measurements: 
3: n=651 (82%) 
2: n=101 (13%) 
1: n=46 (6%) 
Test: n=3 no baseline measurement
Control: n=2 no baseline measurement, 
and n=1 impossible baseline value  
no follow-up measurements
 Test: n=41 
Control: n=43  
In analysis drug levels at steady state:
N=144 
In analysis drug levels at steady state: 
N=147 
No measurements of drug-levels:
Test: n=660 
Control: n=651 
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 416 
FIG 2 Plot of uncorrected data and regression line; and regression lines for Bazett-corrected, 417 
Fridericia-corrected and new-corrected QT (QTcTB), using data at baseline (n=1686) 418 
 419 
Footnote: QT unc-obs  QT uncorrected observed data; QTuncorrected regression line; QTc-F  420 
Fridericia corrected regression line; QTc-Bazett corrected regression line; QTc-TB corrected 421 
regression line using correction factor of 0.4081. 422 
  423 
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424 
425 
 426 
FIG 3 Plot of QTcTB (0.4081)  against 1-RR (where RR=60/heart rate), using data at baseline 427 
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 428 
FIG 4. Boxplots of QTcF values at baseline, months 1 and 2, and end of treatment (month 4 and 6, 429 
respectively) for the gatifloxacin and standard treatment arm. 430 
 431 
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